and is a scientific advisory board member of Repertoire, Aethon Therapeutics, Natures Toolbox and Adventris
The current generation of GLP 1 medications has already changed how clinicians think about weight, metabolism, and long term health, but researchers have always known that the biology of appetite is more complex than a single hormone pathway
orforglipron has filed for FDA approval Molecular type : Orforglipron is a small molecule
Unlike phentermine, GLP-1 drugs target specific receptors in the brain, pancreas, and digestive system to regulate blood sugar, slow gastric emptying, and enhance feelings of fullness
The ob/ob and db/db models, for instance, exhibit key features of human metabolic syndrome and develop hepatic steatosis on a standard diet
While the primary endpoint (cerebral glucose metabolism) was not met, these findings suggest injectable GLP-1s may be more effective than oral formulations